Abstract

Administering asparaginase has always been problematic in adults because most general oncologists who treat adults are not familiar with its usage and toxicity. The toxicity profile of the drug is unique and is not observed with any other chemotherapy agent. Furthermore, asparaginase is almost exclusively used in acute lymphoblastic leukemia (ALL), which is a very rare cancer in adults. Currently, the long-acting pegylated form (pegasparaginase) is the only Escherichia coli–derived asparaginase available in the United States. The use of pediatric regimens is likely to lead to more adult patients receiving multiple doses of pegasparaginase. However, oncologists who treat adults may be reluctant to use pegasparaginase or may unnecessarily discontinue administering it because of certain adverse effects. As a result, the clinical benefit of multiple doses of pegasparaginase will be missed. Despite the fact that pegasparaginase is associated with unique toxicities, the majority are nonfatal, manageable, and reversible. Here, we describe real-life cases of adults with ALL who were treated with pediatric-inspired regimens that incorporated pegasparaginase to illustrate the management of several pegasparaginase-associated adverse effects and guide whether and how to continue the drug.

REFERENCES

REFERENCES
1.
Larson
RA
,
Dodge
RK
,
Linker
CA
, et al
.
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111
.
Blood
.
1998
;
92
(
5
):
1556
-
1564
.
2.
Dinmohamed
AG
,
Szabo
A
,
van der Mark
M
, et al
.
Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival
.
Leukemia
.
2016
;
30
(
2
):
310
-
317
.
3.
McNeer
JL
,
Bleyer
A
.
Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults
.
Pediatr Blood Cancer
.
2018
;
65
(
6
):
e26989
.
4.
Hunger
SP
,
Lu
X
,
Devidas
M
, et al
.
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group
.
J Clin Oncol
.
2012
;
30
(
14
):
1663
-
1669
.
5.
Goldstone
AH
,
Richards
SM
,
Lazarus
HM
, et al
.
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
.
Blood
.
2008
;
111
(
4
):
1827
-
1833
.
6.
Kantarjian
H
,
Thomas
D
,
O’Brien
S
, et al
.
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
.
Cancer
.
2004
;
101
(
12
):
2788
-
2801
.
7.
Moorman
AV
.
The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia
.
Blood Rev
.
2012
;
26
(
3
):
123
-
135
.
8.
Boissel
N
,
Auclerc
MF
,
Lheritier
V
, et al
.
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials
.
J Clin Oncol
.
2003
;
21
(
5
):
774
-
780
.
9.
de Bont
JM
,
Holt
B
,
Dekker
AW
,
van der Does-van den Berg
A
,
Sonneveld
P
,
Pieters
R
.
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands
.
Leukemia
.
2004
;
18
(
12
):
2032
-
2035
.
10.
Ramanujachar
R
,
Richards
S
,
Hann
I
, et al
.
Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials
.
Pediatr Blood Cancer
.
2007
;
48
(
3
):
254
-
261
.
11.
Stock
W
,
La
M
,
Sanford
B
, et al
.
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies
.
Blood
.
2008
;
112
(
5
):
1646
-
1654
.
12.
Stock
W
,
Luger
SM
,
Advani
AS
, et al
.
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
.
Blood
.
2019
;
133
(
14
):
1548
-
1559
.
13.
DeAngelo
DJ
,
Stevenson
KE
,
Dahlberg
SE
, et al
.
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia
.
Leukemia
.
2015
;
29
(
3
):
526
-
534
.
14.
Douer
D
,
Aldoss
I
,
Lunning
MA
, et al
.
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia
.
J Clin Oncol
.
2014
;
32
(
9
):
905
-
911
.
15.
Ribera
JM
,
Oriol
A
,
Sanz
MA
, et al
.
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96
.
J Clin Oncol
.
2008
;
26
(
11
):
1843
-
1849
.
16.
Huguet
F
,
Leguay
T
,
Raffoux
E
, et al
.
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study
.
J Clin Oncol
.
2009
;
27
(
6
):
911
-
918
.
17.
Rijneveld
AW
,
van der Holt
B
,
Daenen
SM
, et al
.
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
.
Leukemia
.
2011
;
25
(
11
):
1697
-
1703
.
18.
Rytting
ME
,
Thomas
DA
,
O’Brien
SM
, et al
.
Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)
.
Cancer
.
2014
;
120
(
23
):
3660
-
3668
.
19.
Sallan
SE
,
Hitchcock-Bryan
S
,
Gelber
R
,
Cassady
JR
,
Frei
E
III
,
Nathan
DG
.
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia
.
Cancer Res
.
1983
;
43
(
11
):
5601
-
5607
.
20.
Nachman
JB
,
Sather
HN
,
Sensel
MG
, et al
.
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
.
N Engl J Med
.
1998
;
338
(
23
):
1663
-
1671
.
21.
Amylon
MD
,
Shuster
J
,
Pullen
J
, et al
.
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study
.
Leukemia
.
1999
;
13
(
3
):
335
-
342
.
22.
Douer
D
.
Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
Best Pract Res Clin Haematol
.
2008
;
21
(
4
):
647
-
658
.
23.
Grace
RF
,
DeAngelo
DJ
,
Stevenson
KE
, et al
.
The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia
.
J Thromb Thrombolysis
.
2018
;
45
(
2
):
306
-
314
.
24.
Albertsen
BK
,
Grell
K
,
Abrahamsson
J
, et al
.
Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: A NOPHO ALL2008 randomized study
.
J Clin Oncol
.
2019
;
37
(
19
):
1638
-
1646
.
25.
DeAngelo
DJ
,
Stevenson
K
,
Neuberg
DS
, et al
.
A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: A DFCI ALL Consortium trial [abstract]
.
Blood
.
2015
;
126
(
23
).
Abstract 80
.
26.
Goekbuget
N
,
Baumann
A
,
Beck
J
, et al
.
PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): Significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) study 07/2003 [abstract]
.
Blood
.
2010
;
116
(
21
).
Abstract 494
.
27.
Douer
D
,
Yampolsky
H
,
Cohen
LJ
, et al
.
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia
.
Blood
.
2007
;
109
(
7
):
2744
-
2750
.
28.
Gökbuget
N
,
Kneba
M
,
Raff
T
, et al
.
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
.
Blood
.
2012
;
120
(
9
):
1868
-
1876
.
29.
Patel
B
,
Kirkwood
AA
,
Dey
A
, et al
.
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
.
Leukemia
.
2017
;
31
(
1
):
58
-
64
.
30.
Appel
IM
,
Kazemier
KM
,
Boos
J
, et al
.
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study
.
Leukemia
.
2008
;
22
(
9
):
1665
-
1679
.
31.
Stock
W
,
Douer
D
,
DeAngelo
DJ
, et al
.
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel
.
Leuk Lymphoma
.
2011
;
52
(
12
):
2237
-
2253
.
32.
Aldoss
I
,
Douer
D
,
Behrendt
CE
, et al
.
Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia
.
Eur J Haematol
.
2016
;
96
(
4
):
375
-
380
.
33.
Liu
Y
,
Smith
CA
,
Panetta
JC
, et al
.
Antibodies predict pegaspargase allergic reactions and failure of rechallenge
.
J Clin Oncol
.
2019
;
37
(
23
):
2051
-
2061
.
34.
Plourde
PV
,
Jeha
S
,
Hijiya
N
, et al
.
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial
.
Pediatr Blood Cancer
.
2014
;
61
(
7
):
1232
-
1238
.
35.
Cooper
SL
,
Young
DJ
,
Bowen
CJ
,
Arwood
NM
,
Poggi
SG
,
Brown
PA
.
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions
.
Pediatr Blood Cancer
.
2019
;
66
(
8
):
e27797
.
36.
Fernandez
CA
,
Smith
C
,
Yang
W
, et al
.
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies
.
Blood
.
2014
;
124
(
8
):
1266
-
1276
.
37.
Maury
S
,
Chevret
S
,
Thomas
X
, et al
.
Rituximab in B-lineage adult acute lymphoblastic leukemia
.
N Engl J Med
.
2016
;
375
(
11
):
1044
-
1053
.
38.
Burke
MJ
,
Devidas
M
,
Maloney
K
, et al
.
Severe pegaspargase hypersensitivity reaction rates (grade >/=3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials
.
Leuk Lymphoma
.
2018
;
59
(
7
):
1624
-
1633
.
39.
Vrooman
LM
,
Stevenson
KE
,
Supko
JG
, et al
.
Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study–Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
.
J Clin Oncol
.
2013
;
31
(
9
):
1202
-
1210
.
40.
Tong
WH
,
Pieters
R
,
Kaspers
GJ
, et al
.
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia
.
Blood
.
2014
;
123
(
13
):
2026
-
2033
.
41.
Pession
A
,
Valsecchi
MG
,
Masera
G
, et al
.
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
.
J Clin Oncol
.
2005
;
23
(
28
):
7161
-
7167
.
42.
van der Sluis
IM
,
Vrooman
LM
,
Pieters
R
, et al
.
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
.
Haematologica
.
2016
;
101
(
3
):
279
-
285
.
43.
Schore
RJ
,
Devidas
M
,
Bleyer
A
, et al
.
Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children’s Oncology Group AALL07P4
.
Leuk Lymphoma
.
2019
;
60
(
7
):
1740
-
1748
.
44.
Salzer
W
,
Bostrom
B
,
Messinger
Y
,
Perissinotti
AJ
,
Marini
B
.
Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia
.
Leuk Lymphoma
.
2018
;
59
(
8
):
1797
-
1806
.
45.
Marini
BL
,
Perissinotti
AJ
,
Bixby
DL
,
Brown
J
,
Burke
PW
.
Catalyzing improvements in ALL therapy with asparaginase
.
Blood Rev
.
2017
;
31
(
5
):
328
-
338
.
46.
Burke
MJ
,
Rheingold
SR
.
Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia
.
Leuk Lymphoma
.
2017
;
58
(
3
):
540
-
551
.
47.
Avramis
VI
,
Sencer
S
,
Periclou
AP
, et al
.
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study
.
Blood
.
2002
;
99
(
6
):
1986
-
1994
.
48.
Salzer
WL
,
Asselin
B
,
Supko
JG
, et al
.
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group
.
Blood
.
2013
;
122
(
4
):
507
-
514
.
49.
Place
AE
,
Stevenson
KE
,
Vrooman
LM
, et al
.
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
.
Lancet Oncol
.
2015
;
16
(
16
):
1677
-
1690
.
50.
Burke
PW
,
Aldoss
I
,
Lunning
MA
, et al
.
Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses
.
Leuk Res
.
2018
;
66
:
49
-
56
.
51.
Rausch
CR
,
Marini
BL
,
Benitez
LL
, et al
.
PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia (dagger)
.
Leuk Lymphoma
.
2018
;
59
(
3
):
617
-
624
.
52.
Geyer
MB
,
Ritchie
EK
,
Rao
AV
, et al
.
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of MRD negativity in adults ages 18-60 with Philadelphia chromosome-negative acute lymphoblastic leukemia and lymphoblastic lymphoma [abstract]
.
Blood
.
2018
;
132
(
suppl 1
).
Abstract 4013
.
53.
Christ
TN
,
Stock
W
,
Knoebel
RW
.
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen
.
J Oncol Pharm Pract
.
2018
;
24
(
4
):
299
-
308
.
54.
Denton
CC
,
Rawlins
YA
,
Oberley
MJ
,
Bhojwani
D
,
Orgel
E
.
Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens
.
Pediatr Blood Cancer
.
2018
;
65
(
3
):
e26891
.
55.
Alachkar
H
,
Fulton
N
,
Sanford
B
, et al
.
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia
.
Pharmacogenomics J
.
2017
;
17
(
3
):
274
-
279
.
56.
Sahoo
S
,
Hart
J
.
Histopathological features of L-asparaginase-induced liver disease
.
Semin Liver Dis
.
2003
;
23
(
3
):
295
-
300
.
57.
Kamal
N
,
Koh
C
,
Samala
N
, et al
.
Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis
.
Hepatol Int
.
2019
;
13
(
5
):
641
-
648
.
58.
Horvat
TZ
,
Pecoraro
JJ
,
Daley
RJ
, et al
.
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance
.
Leuk Res
.
2016
;
50
:
17
-
20
.
59.
Al-Nawakil
C
,
Willems
L
,
Mauprivez
C
, et al
.
Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors
.
Leuk Lymphoma
.
2014
;
55
(
7
):
1670
-
1674
.
60.
Alshiekh-Nasany
R
,
Douer
D
.
L-carnitine for treatment of pegasparaginase-induced hepatotoxicity
.
Acta Haematol
.
2016
;
135
(
4
):
208
-
210
.
61.
Özdemir
ZC
,
Turhan
AB
,
Eren
M
,
Bor
O
.
Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity?
Blood Res
.
2017
;
52
(
1
):
69
-
71
.
62.
Lu
G
,
Karur
V
,
Herrington
JD
,
Walker
MG
.
Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine
.
Proc Bayl Univ Med Cent
.
2016
;
29
(
1
):
46
-
47
.
63.
Roesmann
A
,
Afify
M
,
Panse
J
,
Eisert
A
,
Steitz
J
,
Tolba
RH
.
L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers
.
Chemotherapy
.
2013
;
59
(
3
):
167
-
175
.
64.
Payne
JH
,
Vora
AJ
.
Thrombosis and acute lymphoblastic leukaemia
.
Br J Haematol
.
2007
;
138
(
4
):
430
-
445
.
65.
Truelove
E
,
Fielding
AK
,
Hunt
BJ
.
The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia
.
Leukemia
.
2013
;
27
(
3
):
553
-
559
.
66.
Leone
G
,
Gugliotta
L
,
Mazzucconi
MG
, et al
.
Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study
.
Thromb Haemost
.
1993
;
69
(
1
):
012
-
015
.
67.
Rank
CU
,
Toft
N
,
Tuckuviene
R
, et al
.
Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years
.
Blood
.
2018
;
131
(
22
):
2475
-
2484
.
68.
Grace
RF
,
Dahlberg
SE
,
Neuberg
D
, et al
.
The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols
.
Br J Haematol
.
2011
;
152
(
4
):
452
-
459
.
69.
Nowak-Gött
U
,
Heinecke
A
,
von Kries
R
,
Nurnberger
W
,
Munchow
N
,
Junker
R
.
Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration
.
Thromb Res
.
2001
;
103
(
3
):
165
-
172
.
70.
Couturier
MA
,
Huguet
F
,
Chevallier
P
, et al
.
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience
.
Am J Hematol
.
2015
;
90
(
11
):
986
-
991
.
71.
Mitchell
L
,
Andrew
M
,
Hanna
K
, et al
.
Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study
.
Thromb Haemost
.
2003
;
90
(
2
):
235
-
244
.
72.
Chen
J
,
Ngo
D
,
Aldoss
I
,
Shayani
S
,
Tsai
NC
,
Pullarkat
V
.
Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia
.
Leuk Lymphoma
.
2019
;
60
(
5
):
1187
-
1192
.
73.
Hunault-Berger
M
,
Chevallier
P
,
Delain
M
, et al
.
Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study
.
Haematologica
.
2008
;
93
(
10
):
1488
-
1494
.
74.
Orvain
C
,
Balsat
M
,
Lhéritier
V
, et al
.
Prevention of venous thrombotic events in adult patients with acute lymphoblastic leukemia treated in a pediatric-inspired protocol - a GRAALL Study [abstract]
.
Blood
.
2016
;
128
(
22
).
Abstract 2776
.
75.
Greiner
J
,
Schrappe
M
,
Claviez
A
, et al
.
THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents
.
Haematologica
.
2019
;
104
(
4
):
756
-
765
.
76.
Persson
L
,
Harila-Saari
A
,
Hed Myrberg
I
,
Heyman
M
,
Nilsson
A
,
Ranta
S
.
Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents
.
Pediatr Blood Cancer
.
2017
;
64
(
10
):
e26559
.
77.
Raja
RA
,
Schmiegelow
K
,
Sorensen
DN
,
Frandsen
TL
.
Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia
.
Pediatr Blood Cancer
.
2017
;
64
(
1
):
32
-
38
.
78.
Nussbaum
V
,
Lubcke
N
,
Findlay
R
.
Hyperammonemia secondary to asparaginase: A case series
.
J Oncol Pharm Pract
.
2016
;
22
(
1
):
161
-
164
.
79.
Jörck
C
,
Kiess
W
,
Weigel
JF
,
Mutze
U
,
Bierbach
U
,
Beblo
S
.
Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma
.
Pediatr Hematol Oncol
.
2011
;
28
(
1
):
3
-
9
.
80.
Sudour
H
,
Schmitt
C
,
Contet
A
,
Chastagner
P
,
Feillet
F
.
Acute metabolic encephalopathy in two patients treated with asparaginase and ondasetron
.
Am J Hematol
.
2011
;
86
(
3
):
323
-
325
.
81.
Raja
RA
,
Schmiegelow
K
,
Albertsen
BK
, et al
.
Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol
.
Br J Haematol
.
2014
;
165
(
1
):
126
-
133
.
82.
Wolthers
BO
,
Frandsen
TL
,
Baruchel
A
, et al
.
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study
.
Lancet Oncol
.
2017
;
18
(
9
):
1238
-
1248
.
83.
Oparaji
JA
,
Rose
F
,
Okafor
D
, et al
.
Risk factors for asparaginase-associated pancreatitis: A systematic review
.
J Clin Gastroenterol
.
2017
;
51
(
10
):
907
-
913
.
84.
Wolthers
BO
,
Frandsen
TL
,
Abrahamsson
J
, et al
.
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol
.
Leukemia
.
2017
;
31
(
2
):
325
-
332
.
85.
Kearney
SL
,
Dahlberg
SE
,
Levy
DE
,
Voss
SD
,
Sallan
SE
,
Silverman
LB
.
Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis
.
Pediatr Blood Cancer
.
2009
;
53
(
2
):
162
-
167
.
86.
Sakaguchi
S
,
Higa
T
,
Suzuki
M
,
Fujimura
J
,
Shimizu
T
.
Prophylactic use of octreotide for asparaginase-induced acute pancreatitis
.
Int J Hematol
.
2017
;
106
(
2
):
266
-
268
.
87.
Gupta
S
,
Wang
C
,
Raetz
EA
, et al
.
Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children’s Oncology Group (COG)
.
J Clin Oncol
.
2019
;
37
(
15 suppl
).
Abstract 10005
.
You do not currently have access to this content.